CN101856389A - Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and application thereof - Google Patents
Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and application thereof Download PDFInfo
- Publication number
- CN101856389A CN101856389A CN200910131887A CN200910131887A CN101856389A CN 101856389 A CN101856389 A CN 101856389A CN 200910131887 A CN200910131887 A CN 200910131887A CN 200910131887 A CN200910131887 A CN 200910131887A CN 101856389 A CN101856389 A CN 101856389A
- Authority
- CN
- China
- Prior art keywords
- cerebral
- blood
- acid
- chinese medicinal
- stasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese medicinal preparation which is used for treating cardiovascular and cerebrovascular diseases and contains active ingredients of root of red-rooted salvia, astragalus, ginkgo leaf and leech and application thereof. The Chinese medicinal preparation of the invention comprises oral administration preparations and oral administration slow (controlled) release formulations thereof such as tablets, capsules, soft capsules, granules, syrups, micro-pills, microspheres, ointment, sublimed preparations, injection, suppositories, creams, sprays, patches, micelle, aqueous solution agents, liposome, dextrin inclusion compound and the like. The Chinese medicinal preparation which takes the root of red-rooted salvia, the astragalus, the ginkgo leaf and the leech as main active ingredients has the effects of invigorating blood circulation and dissolving stasis and promoting blood circulation and stopping pain, is suitable for preventing and treating meridians qi-deficiency and blood-stasis type cerebral infarction diseases, arteriosclerosis, coronary heart diseases, angina, acute myocardial infarction, ischemic cerebral apoplexy, cerebral thrombosis and sequelae thereof, high blood viscosity, hyperlipidemia, chronic hypertension, atherosclerosis, chest obstruction, cardiodynia, megrim, chest stuffiness and cardiodynia caused by agglomeration of phlegm and blood stasis, can reduce vertebral artery resistance obviously and improve cerebral ischemia and cerebral blood circulation, and can be used for disseminated intravascular coagulation, and the absorption of intracerebral hematoma of the cerebral hemorrhage convalescence and sequelae.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation and application thereof that contains the treatment cardiovascular and cerebrovascular disease of Radix Salviae Miltiorrhizae, the Radix Astragali, Folium Ginkgo and leech active composition.The form of Chinese drug that the present invention relates to comprises oral formulations and oral slow (control) release dosage forms thereof such as tablet, capsule and soft capsule, granule, syrup, pellet, microspheres agent, unguentum, sublimed preparation, injection, suppository, cream, spray, patch, micelle, water preparation, liposome, cyclodextrin inclusion compound.With Radix Salviae Miltiorrhizae, the Radix Astragali, Folium Ginkgo and Hirudo are the Chinese medicine preparation blood circulation promoting and blood stasis dispelling of main active, coronary circulation-promoting pain-relieving, be applicable to prevention and treatment meridians Qi deficiency blood stasis type cerebral infarction disease, arteriosclerosis, coronary heart disease, angina pectoris, acute myocardial infarction, ischemia apoplexy, cerebral thrombosis and sequela thereof, the high viscosity of learning, hyperlipidemia, chronic hypertension, the sclerosis of tremulous pulse medicated porridge, obstruction of qi in the chest and cardialgia, dizzy, uncomfortable in chest and pained genus expectorant stasis of blood cohesion person, can significantly reduce the vertebral artery resistance, improve cerebral ischemia and brain blood circulation, also can be used for disseminated inravascular coagulation, the absorption of the intracerebral hematoma of cerebral hemorrhage convalescent period and sequela.
Background technology
Cardiovascular and cerebrovascular disease is commonly encountered diseases, the frequently-occurring disease that threatens human health, rises to human three one of the reasons of dying of illness greatly year by year as the mortality rate of coronary heart disease, angina pectoris, myocardial infarction, has surpassed cancer at its mortality rate of China.And along with China along with the raising of living standards of the people and the aging of population structure, the patient colony of cardiovascular disease is huge day by day.The method and the medicine of integrative therapy cardiovascular and cerebrovascular disease are a lot, Chinese medicine particularly, and because of the curative effect height, toxic and side effects is little, has original advantage.
Radix Salviae Miltiorrhizae another name Radix Salviae Miltiorrhizae, Herba Wedeliae Wallichii, Radix Campylotropis Hirtella (Herba Myrsines Africanae), Arisaema balansae Engl. etc.For Labiatae Radix Salviae Miltiorrhizae (Salvia miltiorrhiza Bge), be used as medicine with root.Contain Tanshinone I, II A, II B, iso tanshinone I, II A, cryptotanshinone, different cryptotanshinone, methyltanshinone, hydroxyl TANSHINONES etc., of many uses, be mainly used in stasis-dispelling and pain-killing, promoting blood flow to regulate menstruation, the relieving restlessness etc. of nourishing heart, fine to coronary heart disease, cardiovascular diseases's informal dress curative effect.Radix Salviae Miltiorrhizae extract is in cerebral ischemia reperfusion injury; can reduce ischemic region glutamic acid content; obvious blood flow increasing; reduce leukocyte in the peripheral blood; CD18 and CD11b immune molecule number suppress the inflammatory reaction and the neuronic necrosis of ischemic injuries kitchen range, have the cerebral edema of alleviating; reduce the toxicity of NO, the neuroprotective of effects such as anti peroxidation of lipid after for ischemia has effect preferably.
Semen Ginkgo extrac is the extract of dry Folium Ginkgo, the apricot yellow ketone of argentiferous 〉=24% wherein, Ginkgo total lactones 〉=6%.Cardiovascular and cerebrovascular disease such as treatment coronary heart disease, angina pectoris, scheming infarction, cerebral embolism and respiratory system disease there are significant curative effect, are mainly used in coronary atherosclerotic heart disease.Contained ginkgolide B may pass through to reduce phosphate A2 and hemolytic phosphate esterase active, and antagonism platelet activating factor (PAF) receptor has reduced the platelet height state of activation, has alleviated brain injury.Ginkgolide B also is the neurovirulent main component of antiglutamic acid.The contained ginkgetin of EGb has stronger antioxidation.
Hirudo is the dry body of Hirudinidae animal.Salty in the mouth, hardship, property is flat.Have removing blood stasis, removing blood stasis, the effect of stimulating the menstrual flow.Be used for the blood stasis amenorrhea, diseases such as traumatic injury.China's pharmacology monograph Shennong's Herbal the earliest carries Hirudo " by stagnant blood congestion ".Hirudo contains aminoacid, polypeptide constituents, contains micro-hirudin in the Hirudo live body salivary gland, has blood coagulation resisting function.The water decoction of clinical use dry product Hirudo truly has anticoagulation, shows that other compositions such as polypeptide, protease also have active function.The decocting liquid of Hirudo is live part.The clinical apoplexy that is usually used in, hemiplegia, facial hemiparalysis more is applicable to diseases such as the cerebrology behind the high pressure cerebral hemorrhage is swollen, cerebral thrombosis; And the toxic and side effects of Hirudo is minimum.
The Radix Astragali contains saponins, flavone, aminoacid, polysaccharide and trace element etc.At least contain 3 kinds of saponin in the Radix Astragali, have blood pressure lowering, diuresis, cardiotonic.Also contain osajin, the bright florigen of awns and calycosin etc.Kind of free amino acid surplus containing 20 in the Radix Astragali, wherein more with the content of east, sky amide, canavanine, proline, arginine, aspartic acid R-aminobutyric acid, alanine.Contain multiple polysaccharide in the Radix Astragali immunologic enhancement is arranged.Contain 14 kinds of trace element in the Radix Astragali, wherein higher with ferrum, manganese, selenic content.
The cardiovascular and cerebrovascular disease cause of disease and pathogenesis complexity are the diseases of a deficiency in origin and excess in superficiality.Sick deficiency of qi and blood, the imbalance of YIN and YANG of originally being.Being marked on of disease is turbid in blood stasis, expectorant, wind-fire, QI rising in reverse order etc.Though cardiovascular and cerebrovascular disease sees that disease is different, the blood stasis pathogenesis is identical.The special effect of diagnostic techniques such as MRI and CT in recent years makes medical circle to the blood stasis pathogenesis clear and definite understanding arranged.Thereby clinical treatment cardiovascular and cerebrovascular disease will pay attention to from start to finish cremating congestion in the dissipation cerebral blood vessel.
Deficient, blood stasis, turbid, the normal again reciprocal causation of wind-fire of expectorant affect PD.Gas can not then be transported unable, the hematogenous blockage of blood by handsome blood, stagnates and the stasis of blood.The deficiency of vital energy can not transmitting and distributing the fluids and essence of water and grain, so that the turbid stagnation of the phlegm-damp stasis of blood.Blood stasis obstructing airway, so that the turbid stagnation of expectorant.The turbid mechanism of qi that can block of expectorant follows row, causes qi depression to blood stasis.So blood stasis due to qi deficiency is one of basic pathogenesis of cardiovascular and cerebrovascular disease, also is clinical main cardiovascular and cerebrovascular disease pattern of syndrome.The Therapeutic Principle adopts tonification vigour, activating blood circulation to dissipate blood stasis two method combinations.
Chinese medicine preparation of the present invention adopts the protection to brain neuron of Radix Salviae Miltiorrhizae and Folium Ginkgo, and Radix Astragali QI invigorating, Hirudoization silt match, and QI invigorating is effected a permanent cure, and takes stopgap measures by becoming silted up, make QI invigorating product the power tonify without causing stagnation of change silt mediation; The product of making silt the power of QI invigorating promotion is not lost vigour.Benefiting QI for activating blood circulation and usefulness make unit be so incensed that multiple, and congestion must be dispelled, and guarantees curative effect.
Summary of the invention
The present invention relates to a kind of Chinese medicine preparation and application thereof that contains Radix Salviae Miltiorrhizae, the Radix Astragali, Folium Ginkgo and leech active composition.Described Chinese medicine preparation is an active component with natural Radix Salviae Miltiorrhizae, the Radix Astragali, Folium Ginkgo and Hirudo or its extract, adds adjuvants such as relevant dispersant, antiseptic.
Pharmaceutical preparation of the present invention can be any pharmaceutically useful dosage form, and the dosage form of Chinese medicine preparation comprises oral formulations and oral slow (control) release dosage forms thereof such as tablet, capsule and soft capsule, granule, syrup, pellet, microspheres agent, unguentum, sublimed preparation, injection, suppository, cream, spray, patch, micelle, water preparation, liposome, cyclodextrin inclusion compound.The effective ingredient high degree of dispersion that can make medicine is in substrate, and is not only rapid-action, the curative effect height, and physicochemical property, pharmacodynamic stability are better, taking convenience, the bioavailability height can cover the bad flavor of smelling of medicine, and the patient is easy to characteristics such as acceptance.
Slow (control) release formulation technology for medicine comprises following aspect: make the little complex of dissolubility, with macromolecular compound generation insoluble chemical compound, be hidden in pharmaceutical pack in the turbid solubility skeleton or in the hydrophilic colloid, with coating blocker coating, be made for capsule or insoluble matrix tablet, make Emulsion, make osmotic pump controlled release tablet.
Pharmaceutical preparation of the present invention, the preparation of its oral administration can contain excipient commonly used, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to tablet in case of necessity.Contain following material in the various preparations: oil infiltration agent such as glyceryl monostearate, castor oil hydrogenated, Dormant oils, polysiloxanes, dimethyl polysiloxane etc.; Hydrophilic colloid such as cellulose derivative, arabic gum, sodium alginate, card wave spectrum etc.; Coating blocker such as allyl resin; Other polymer such as polylactic acid, polypropylene, polyvinyl alcohol, ethylene-vinyl acetate copolymer, Polyethylene Glycol, poly-acetic acid, polyglycolic acid, polyamino acid etc.; Antiseptic is one or more in sorbic acid, sorbic acid methyl ester, methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, the benzoic acid.The filler that is suitable for comprises cellulose, mannitol, lactose and other similar filleies.Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate.Suitable lubricant, for example magnesium stearate.The acceptable wetting agent of appropriate drug comprises sodium lauryl sulphate.When being prepared into medicament, optionally add suitable medicine acceptable carrier, described medicine acceptable carrier is selected from: mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, the gold-plating guanidine-acetic acid, methionine, vitamin C, the EDTA disodium, EDTA calcium sodium, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, the Fructus Jujubae hydrochlorate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
The Chinese medicine preparation that contains Radix Salviae Miltiorrhizae, the Radix Astragali, Folium Ginkgo and leech active composition can be made up of following weight proportion: Hirudo 1-10%; Radix Salviae Miltiorrhizae 5-30%; Folium Ginkgo 10-40%; Radix Astragali 3-30%; Dispersant 1-10%; Antiseptic 01-5%.
Chinese medicine preparation of the present invention is to process through extraction or additive method by the raw material of Chinese medicine that above-mentioned prescription is formed, and makes pharmaceutically active substance, is raw material with this material, adds the medicine acceptable carrier when needing, and makes according to the routine techniques of galenic pharmacy.Described active substance can obtain by extracting raw material of Chinese medicine respectively, also can obtain by the co-extracted raw material of Chinese medicine, also can obtain by other modes, as: by pulverize, press stockaded village, calcining, grind, sieve, permeate, extraction, water are carried, alcohol extraction, ester are carried, methods such as ketone is carried, chromatography obtain, these active substances can be the materials that extractum shape is told, can be that dry extract also can be a fluid extract, make different concentration according to the different needs decision of preparation.
The extraction of active ingredient of Chinese herbs generally adopts the water body alcohol deposition method refining, filters, and the filtrate vacuum drying was pulverized the 80-100 mesh sieve, got the pressed powder of extract.
The Radix Salviae Miltiorrhizae extraction of active ingredients: add 10 times of amounts, 8 times of amount 80% alcohol reflux secondaries after Radix Notoginseng is pulverized respectively, the time was respectively 2 hours, extracted back recovery ethanol in 2 hours, add water carry out water precipitating after centrifugal D
101Macroporous resin, the resin absorption post washes remove impurity with water, and reuse 80% ethanol carries out desorbing, collects desorbed solution, has reclaimed the exsiccant dried cream of ethanol final vacuum, and dried cream adds 80% ethanol extraction promptly.
Folium Ginkgo extraction of active ingredients: add 10 times of amounts, 8 times of amount 80% alcohol reflux secondaries after dry Folium Ginkgo is pulverized respectively, time was respectively 2 hours, extract the back and reclaimed ethanol, add water and sink centrifugal back resin absorption, wash remove impurity with water, reuse 80% ethanol carries out desorbing, collects desorbed solution, reclaimed the dried cream of ethanol after drying, dried cream adds 90% ethanol extraction promptly.
The extraction of leech active composition: Hirudo is pulverized, and adds 5 times of amount normal saline, fully stirs, and places 10 hours for 5 ℃, and inclining supernatant, extracts 3 times merge extractive liquid, with method.Extracting solution is transferred about pH value to 5 with acetic acid, places 10 hours for 5 ℃, and sucking filtration gets supernatant.Supernatant is transferred pH value to 6 with 20% sodium hydroxide solution, adds ethanol then and makes and contain alcohol and reach 80%, places, and crosses the leaching precipitation, gets the leech active composition with cold drying behind 75% ethanol elution.
Radix Astragali extraction of active ingredients: the Radix Astragali is cut the 1mm decoction pieces, adds 12 times of amounts of water, soaks 5 hours, decoct and extract 3 times, each 2 hours, merge three times decoction liquor, filter, filtrate decompression is concentrated into proportion 1.10, put coldly, add ethanol and make that to contain the alcohol amount be 80%, standing over night, getting supernatant decompression recycling ethanol to concentrated solution does not have the alcohol flavor, and cold drying promptly.
The Chinese medicine preparation blood circulation promoting and blood stasis dispelling of the medicine involved in the present invention and the extract of compositions thereof, coronary circulation-promoting pain-relieving, be applicable to prevention and treatment meridians Qi deficiency blood stasis type cerebral infarction disease, arteriosclerosis, coronary heart disease, angina pectoris, acute myocardial infarction, ischemia apoplexy, cerebral thrombosis and sequela thereof, the high viscosity of learning, hyperlipidemia, chronic hypertension, the sclerosis of tremulous pulse medicated porridge, obstruction of qi in the chest and cardialgia, dizzy, uncomfortable in chest and pained genus expectorant stasis of blood cohesion person, can significantly reduce the vertebral artery resistance, improve cerebral ischemia and brain blood circulation, also can be used for disseminated inravascular coagulation, the absorption of the intracerebral hematoma of cerebral hemorrhage convalescent period and sequela.
Product of the present invention prepares as stated above, and its detailed component is provided by the following example, but protection scope of the present invention is not limited to this.
The specific embodiment
Specify the present invention with embodiment below, these embodiment should not be construed as going up in all senses the present invention are construed as limiting.
Embodiment 1 capsule prescription (1
#)
Radix Salviae Miltiorrhizae extract 500g
Folium Ginkgo extract 1200g
Hirudo extract 500g
Radix Astragali extract 800g
Adjuvant 1000g
Ethylparaben 0.5g
Make 1000 altogether
Preparation method:
Get that above four kinds of extraction of active ingredients things are pulverized, behind the mix homogeneously, add a certain amount of adjuvant mix homogeneously and incapsulate, make 1000 capsules (0.4g/ grain), reinstall in the bottle after aluminum-plastic packaged and seal.
Embodiment 2 tablet formulations (2
#)
Radix Salviae Miltiorrhizae extract 400g
Folium Ginkgo extract 1000g
Hirudo extract 500g
Radix Astragali extract 800g
Right amount of auxiliary materials
Benzoic acid 1.5g
Make 1000 altogether
Get activity extract, behind the adjuvant mix homogeneously, adopt 5% starch slurry system soft material, 18 mesh sieves are granulated, 40 ℃ of dryings, and 16 mesh sieve granulate, behind the adding carboxymethyl starch sodium mix homogeneously, compacting is in flakes.
Embodiment 3 enteric coated tablets prescriptions (3#)
The label prescription:
Radix Salviae Miltiorrhizae extract 600g
Folium Ginkgo extract 800g
Hirudo extract 400g
Radix Astragali extract 1000g
5% starch slurry is an amount of
Starch 100g
Benzoic acid 2.5g
Make 1000 altogether
Coating fluid prescription:
PVAP 10％
Diethyl phthalate 5%
Pulvis Talci 2%
Acetone (1: 1) adds to 100%
Preparation method:
Get activity extract, behind the starch mix homogeneously, adopt 5% starch slurry system soft material, 30 mesh sieves are granulated, 50 ℃ of dryings, and 20 mesh sieve granulate, behind the adding carboxymethyl starch sodium mix homogeneously, the label of compacting.PVAP, diethyl phthalate, Pulvis Talci are joined in proper amount of acetone/alcohol mixeding liquid, and airtight, about 2 hours of magnetic agitation continues and adds the acetone mixed liquor to full dose, continues stir about and gets final product in 1 hour.Above label is carried out coating, notice in the coating process that spray velocity, the flowing velocity of slice, thin piece, the rate of drying of coating solution is inter-adhesive to prevent between the tablet.After coating is finished,, get final product in about 1 hour of 50 ℃ of dryings.
Embodiment 4 enterics drip nine doses of prescriptions (4#)
Prescription:
Radix Salviae Miltiorrhizae extract 400g
Folium Ginkgo extract 700g
Hirudo extract 200g
Radix Astragali extract 800g
Propylene glycol 5g
Make 1000 altogether
Coating fluid prescription:
Eudragit?R 15％
Citric acid three ester 6%
Glycerol 5%
Pulvis Talci 3%
Ethanol adds to 100%
Preparation method:
After stearic acid three esters of getting recipe quantity are heated to fusion, treat that it is cooled to about 50 ℃, add activity extract, stirring, regulate the water dropper size system of dripping, is coolant with dimethicone or liquid paraffin, chilling temperature is about-10 ℃, selects ball, is drying to obtain.Eudragit R, citric acid three ester added in 80% the alcoholic solution and dissolve, stir about 3 hours at a slow speed under magnetic stirring apparatus makes it dissolving fully, adds surplus ethanol and Pulvis Talci, glycerol, and continuing to stir is to get final product in 1 hour.Drop pill is placed coating pan, and control inlet temperature and hydrojet speed prevent the drop pill adhesion, and coating is carried out smoothly.After coating finishes, dry getting final product.
Embodiment 5 granules prescription (5
#)
Radix Salviae Miltiorrhizae extract 50g
Folium Ginkgo extract 150g
Hirudo extract 20g
Radix Astragali extract 100g
Right amount of auxiliary materials
Ethylparaben 2.5g
Make 1000 bags altogether.
After getting above two kinds of active component pulverizing, mix homogeneously, add a certain amount of adjuvant mix homogeneously, make soft material in right amount with ethanol, the system granule, cold drying, granulate gets granule 1000g, is distributed into bag (a 1g/ bag).
Embodiment 6: to the pharmacodynamics test of rat myocardium block
Rat is divided into 7 groups at random by body weight, 10 every group, promptly 1
#-5
#Sample sets, positive control drug Piracetam Capsule group (50mg/kg), model control group (waiting the capacity solvent).Medicine is pressed dosage, is made into suitable concentration respectively with Sodium Tvlose, and gastric infusion is irritated stomach every day 2 times.Model control group is irritated the isometric Sodium Tvlose solution of stomach.Continuous irrigation stomach 4 days after the anesthesia, practices artificial respiration the animal endotracheal intubation.Go out to cut off the 3rd rib in left border of sternum 0.5cm and open breast, open pericardium after exposing the thoracic cavity, with silk thread intersection ligation left anterior descending coronary artery below pulmonary artery and left auricle lower edge, show that with left chamber antetheca cyanosis or bluish violet and electrocardiogram moving on the ST section more than the 0.2mV is that ligation successfully indicates, heart is put back in the thoracic cavity, sewed up thoracic wall.
Ventricle is got blood 3ml behind coronary ligation 3h.Win rat heart then and send new intracavity hematocele, inhale the branch that anhydrates, reject non-cardiac muscular tissue, wipe out atrium and right ventricle, stay left ventricle and weigh with normal saline flushing and with filter paper.Ventricle is cut into myocardium sheet, puts into buffer, dyeing, infarcted region is not peony, and infarcted region is white in color, and separates in the myocardium sheet infarcted region and weighs, and calculating infarcted region (weight in wet base), to account for left ventricle (weight in wet base) percentage ratio be the heart infarction scope.As a result, model control group has tangible ischemia phenomenon, and infarction size accounts for 33.1%, 1 of left ventricle
#-5
#Sample sets and Naoxuekang capsule for curing cerebrovascular disease group all can be observed the effect that significantly resists myocardial ischemia, and myocardial infarct size obviously dwindles (P＜0.01),
Influence to myocardial infarct size behind the rat coronary ligation
Group heart infarction scope (%, heart infarction district/left chamber weight in wet base)
1
# 10.2±1.3
2
# 11.6±1.5
3
# 11.4±1.1
4
# 10.8±1.5
5
# 9.4±1.4
Model control group 33.1 ± 2.3
Naoxuekang capsule for curing cerebrovascular disease group 19.2 ± 1.2
Annotate: compare P＜0.05 with model control group
Embodiment 10: to the pharmacodynamics test of rat myocardium block
Select the Wistar rat, male and female half and half, body weight 220-280 gram is divided into 7 groups at random, 12 every group, irritates stomach in preceding 24 hours and 1 hour respectively at test and awards 1
#-5
#Sample by 3g/kg (being equivalent to people's equivalent) and etc. the dosage NIAOXUEKANG, and the matched group tap water, irritate stomach volume 0.5ml/100g, do thrombotic inhibitory action test.
Rat test of pesticide effectiveness result
Organize the wet amount of routine dosage (g/kg) thrombosis (mg) suppression ratio (100%)
Matched group/39 ± 70
1
# 3.0 11±3# 74
2
# 3.0 12±4# 71
3
# 3.0 10±3# 78
4
# 3.0 11±1# 76
5
# 3.0 12±3# 77
NIAOXUEKANG 0.3 17 ± 3# 56
Annotate relatively P＜0.01 of # and matched group
Experimental result shows 1
#-5
#The inhibitory action that sample forms rat suppository all significantly is better than the NIAOXUEKANG of corresponding dosage.
Embodiment 7: the toxicological study result
Acute toxicity test: it is 50g/kg (medicine/body weight) that mice once gavages maximum dose, is 250 times of clinical maximum consumption per day, illustrates that it is safe and reliable that said preparation is intended consumption clinically.
Long term toxicity test: respectively to nine weeks of rat oral gavage, the result shows: soft capsule test group platelet count obviously reduces with difference prescription soft capsule 0.5,1.0, three dosage of 4.0g/kg and normal saline, and conventional other index of rat serum is not had obvious effect; Administration group serum biochemistry index is starkly lower than matched group, and the administration treated animal heart, liver weight coefficient are lower than matched group, but can recover after two weeks of drug withdrawal, all the other internal organs spleens, lung, kidney device weight coefficient and the equal no significant difference of matched group; The pathological examination animal heart, liver, spleen, lung, kidney are not found obviously unusual.
Those skilled in the art's book according to the above description carry out various modifications and change to compositions and method.All such modifications in the appended claims scope all are included in the scope of the present invention.
Claims (5)
1. the present invention relates to a kind of Chinese medicine preparation and application thereof that contains the treatment cardiovascular and cerebrovascular disease of Radix Salviae Miltiorrhizae, the Radix Astragali, Folium Ginkgo and leech active composition.
2. described dosage form comprises oral formulations and oral slow (control) release dosage form thereof of tablet, capsule and soft capsule, granule, syrup, pellet, microspheres agent, unguentum, sublimed preparation, injection, suppository, cream, spray, patch, micelle, water preparation, liposome, cyclodextrin inclusion compound.
3. aforementioned claim 1 contains following material to the desired medicine of claim 2: oil infiltration agent such as glyceryl monostearate, castor oil hydrogenated, Dormant oils, polysiloxanes, dimethyl polysiloxane; Hydrophilic colloid such as cellulose derivative, arabic gum, sodium alginate, card wave spectrum etc.; Coating blocker such as allyl resin; Other polymer such as polylactic acid, polypropylene, polyvinyl alcohol, ethylene-vinyl acetate copolymer), Polyethylene Glycol, poly-acetic acid, polyglycolic acid, polyamino acid; Antiseptic is one or more in sorbic acid, sorbic acid methyl ester, methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, the benzoic acid.
4. aforementioned claim 1 to the desired pharmaceutical composition of claim 3 is made up of following weight proportion: Hirudo 1-10%; Radix Salviae Miltiorrhizae 5-30%; Folium Ginkgo 10-40%; Radix Astragali 3-30%; Dispersant 1-10%; Antiseptic 0.1-5%.
5. weigh aforementioned claim 1 to the desired pharmaceutical composition blood circulation promoting and blood stasis dispelling of claim 4, coronary circulation-promoting pain-relieving, be applicable to prevention and treatment meridians Qi deficiency blood stasis type cerebral infarction disease, arteriosclerosis, coronary heart disease, angina pectoris, acute myocardial infarction, ischemia apoplexy, cerebral thrombosis and sequela thereof, the high viscosity of learning, hyperlipidemia, chronic hypertension, the sclerosis of tremulous pulse medicated porridge, obstruction of qi in the chest and cardialgia, dizzy, uncomfortable in chest and pained genus expectorant stasis of blood cohesion person, can significantly reduce the vertebral artery resistance, improve cerebral ischemia and brain blood circulation, also can be used for disseminated inravascular coagulation, the absorption of the intracerebral hematoma of cerebral hemorrhage convalescent period and sequela.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910131887A CN101856389A (en) | 2009-04-09 | 2009-04-09 | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910131887A CN101856389A (en) | 2009-04-09 | 2009-04-09 | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101856389A true CN101856389A (en) | 2010-10-13 |
Family
ID=42942693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910131887A Pending CN101856389A (en) | 2009-04-09 | 2009-04-09 | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101856389A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105327145A (en) * | 2015-11-28 | 2016-02-17 | 王文福 | Composition for treating hypertensive cerebral hemorrhage and preparation method thereof |
| CN109568500A (en) * | 2018-12-13 | 2019-04-05 | 张辉 | A kind of Chinese medicine and its preparation process prevented or treat hypertensive stroke |
| US11168287B2 (en) | 2016-05-26 | 2021-11-09 | Kimberly-Clark Worldwide, Inc. | Anti-adherent compositions and methods of inhibiting the adherence of microbes to a surface |
| US11737458B2 (en) | 2015-04-01 | 2023-08-29 | Kimberly-Clark Worldwide, Inc. | Fibrous substrate for capture of gram negative bacteria |
| US12037497B2 (en) | 2016-01-28 | 2024-07-16 | Kimberly-Clark Worldwide, Inc. | Anti-adherent composition against DNA viruses and method of inhibiting the adherence of DNA viruses to a surface |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1985965A (en) * | 2006-07-23 | 2007-06-27 | 李锡尧 | Medicine for treating coronary heart disease and cerebral thrombus and its preparing method |
| CN101085024A (en) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | Traditional Chinese medicinal composition containing red sage root and ginkgo leaves and its preparation |
-
2009
- 2009-04-09 CN CN200910131887A patent/CN101856389A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085024A (en) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | Traditional Chinese medicinal composition containing red sage root and ginkgo leaves and its preparation |
| CN1985965A (en) * | 2006-07-23 | 2007-06-27 | 李锡尧 | Medicine for treating coronary heart disease and cerebral thrombus and its preparing method |
Non-Patent Citations (1)
| Title |
|---|
| 王佟等: "水蛭胶囊配合复方丹参及黄芪治疗不稳定型心绞痛疗效观察", 《医学研究杂志》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11737458B2 (en) | 2015-04-01 | 2023-08-29 | Kimberly-Clark Worldwide, Inc. | Fibrous substrate for capture of gram negative bacteria |
| CN105327145A (en) * | 2015-11-28 | 2016-02-17 | 王文福 | Composition for treating hypertensive cerebral hemorrhage and preparation method thereof |
| US12037497B2 (en) | 2016-01-28 | 2024-07-16 | Kimberly-Clark Worldwide, Inc. | Anti-adherent composition against DNA viruses and method of inhibiting the adherence of DNA viruses to a surface |
| US11168287B2 (en) | 2016-05-26 | 2021-11-09 | Kimberly-Clark Worldwide, Inc. | Anti-adherent compositions and methods of inhibiting the adherence of microbes to a surface |
| CN109568500A (en) * | 2018-12-13 | 2019-04-05 | 张辉 | A kind of Chinese medicine and its preparation process prevented or treat hypertensive stroke |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103623341A (en) | Drug for treating hypertension and cardiovascular and cerebrovascular diseases caused by hypertension | |
| CN105267943A (en) | Lumbricus bioactive small peptide effective part composition | |
| CN102293927B (en) | Compound Chinese medicinal preparation with antifatigue and antioxidation effects, and preparation method thereof | |
| CN104173264A (en) | Rose essence oil hydrogel patch and preparation method thereof | |
| CN101856389A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and application thereof | |
| CN104758806A (en) | Decocted extract for treating coronary heart disease and preparation method thereof | |
| CN101884661A (en) | Traditional Chinese medical preparation containing leeches and astragalus and used for treating cardiovascular and cerebrovascular diseases | |
| CN101700275A (en) | A medicinal preparation containing jujube and its preparation method and application | |
| CN103830436A (en) | Traditional Chinese medicine composition for treating hypertension and preparation method thereof | |
| CN102657795A (en) | Traditional Chinese medicine preparation for promoting postoperative incision healing | |
| CN102293985B (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
| CN103182008A (en) | Preparation method for traditional Chinese medicine used for stabilizing and reducing blood pressure | |
| CN109731074A (en) | A kind of for oral administration and external application suit and preparation method thereof for alleviating asthenopia and xerophthalmia | |
| CN1180821C (en) | Medicine for treating cerebral thrombus and its prepn | |
| CN101485786A (en) | Whitening spot-eliminating composition and method for preparing the same | |
| CN103127272A (en) | Chinese medicinal preparation for treating breast disease and preparation method thereof | |
| CN103494916B (en) | Traditional Chinese medicine composition with effect of reducing blood sugar, as well as preparation method and application thereof | |
| CN1887324B (en) | Chinese medicine composition for treating liver and kidney defect, and its preparation process and analysis method | |
| CN102293923A (en) | Application of Tibetan medicinal composition to preparation of medicament for preventing and treating osteoporosis | |
| CN105687522A (en) | Pharmaceutical composition with chloasma removing function and preparation method thereof | |
| CN101313989B (en) | Chinese medicinal composition for treating coronary disease, stenocardia | |
| CN1321484A (en) | Medicine for curing coronary heart disease with hypertension and its preparation process | |
| CN103431387B (en) | Whitening and freckle-removing traditional Chinese medicine composition and preparation process thereof | |
| CN104147186A (en) | Rose essential oil hydrogel plaster and preparation method thereof | |
| CN1229122C (en) | Combination of Chinese herbal medicine for treating high blood pressure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20101013 |